Clinical Report: Mavacamten Treatment Associated With Improved Diastolic Function

Overview

An interim analysis of 465 patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten showed significant improvements in diastolic function and cardiac remodeling markers over 18 months.

Background

Mavacamten is a selective cardiac-specific myosin inhibitor approved for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This condition is characterized by diastolic dysfunction and can lead to significant morbidity. Understanding the effects of mavacamten on diastolic function and cardiac remodeling is crucial for optimizing treatment strategies in oHCM.

Data Highlights

Key Findings

• Significant increase in medial e′ velocity from 0.05 m/s to 0.06 m/s.
• Significant increase in lateral e′ velocity from 0.07 m/s to 0.08 m/s.
• Significant decrease in average E/e′ ratio from 17.4 to 14.2.
• Significant decrease in left ventricular wall thickness from 18.5 mm to 17.6 mm.
• Significant decrease in left ventricular mass index from 126.3 g/m² to 117.6 g/m².
• Significant decrease in left atrial volume index from 45.5 mL/m² to 38.4 mL/m².

Clinical Implications

The findings indicate improvements in diastolic function and cardiac remodeling in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Conclusion

The interim analysis indicates that mavacamten is associated with significant improvements in echocardiographic markers of diastolic function and cardiac remodeling in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Related Resources & Content

1. Journal of the American Society of Echocardiography, 2024 -- Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers
2. phoenix children's medical connection — Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
3. Journal of Cardiac Failure — Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
4. Clinical Research in Cardiology — Clinical Insights on Starting Mavacamten Treatment in Outpatient Settings During a 12-Week Titration Phase for Hypertrophic Cardiomyopathy
5. Clinical Research in Cardiology — Mavacamten Enhances Myocardial Performance in Individuals with Obstructive Hypertrophic Cardiomyopathy: Insights from Non-Invasive Pressure-Strain Assessment
6. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
7. Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
8. Clinical Insights on Starting Mavacamten Treatment in Outpatient Settings During a 12-Week Titration Phase for Hypertrophic Cardiomyopathy
9. Mavacamten Enhances Myocardial Performance in Individuals with Obstructive Hypertrophic Cardiomyopathy: Insights from Non-Invasive Pressure-Strain Assessment
10. Exercise, New Drug Class Recommended for Management of Hypertrophic Cardiomyopathy
11. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
12. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy